MolNFT v1 · #159679 · protein
HIV-1 protease NL4-3 wt in complex with LR2-91
6OXO: “HIV-1 protease NL4-3 wt in complex with LR2-91”. X-ray diffraction, 2 ligands (NJM, SO4), 1 pocket (best druggability 0.71). MolNFT v1 #159679 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 6OXO
- Type
- protein
- Length
- 198 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Protease NL4-3
- UniProt
- Q8ULI9
- Ligands
- NJM, SO4
- Pockets
- 1 · best druggability 0.71
Structure
x-ray diffraction · 1 distinct chain · 7% helix, 56% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| B, A | Protease NL4-3 | protein | 99 | 7% helix, 56% strand | Q8ULI9 |
Ligands and binding sites
- NJM · (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl {(2S,3R)-3-hydroxy-4-[{[4-(hydroxymethyl)phenyl]sulfonyl}(2-methylpropyl)amino]-1-phenylbutan-2-yl}carbamate · ligand · chains B, A
- SO4 · Sulfate ion · ion · 5 copies · chains B, A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 397 | 0.71 | 0.82 | 35 | NJM |
Interfaces
1 interface between chains.
- B–A · 1850 Ų buried · 40 hydrogen bonds · protein-protein
Compared structures
- 6OXO · HIV-1 Protease NL4-3 WT in Complex with LR2-91 · the same entry in another collection · chain B against B, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q8ULI9
- Elsewhere: RCSB PDB 6OXO · PDBe 6OXO · UniProt Q8ULI9
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.